PCRX
Pacira BioSciences Inc (PCRX)
Healthcare • NASDAQ • $23.96+1.91%
- Symbol
- PCRX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $23.96
- Daily Change
- +1.91%
- Market Cap
- $878.64M
- Trailing P/E
- 171.77
- Forward P/E
- 6.12
- 52W High
- $27.64
- 52W Low
- $18.80
- Analyst Target
- $29.67
- Dividend Yield
- N/A
- Beta
- 0.29
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medici…
Company websiteResearch PCRX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.